Efung Capital

Efung Capital is one of the earliest specialized biopharmaceutical investment institutions in China. Its investment team consists of a group of biopharmaceutical Ph.D.s from top universities both domestically and internationally. Focused on global biopharmaceutical VC/PE investments, Efung Capital has deeply screened and invested in high-quality companies such as Chipscreen Biosciences, Frontier Biotechnologies, Ascentage Pharma, Pulnovo Medical, Harbour BioMed, Hycyte Biotechnology, Aosaikang Pharmaceutical, 3D Medicines, Genuine Biotech, Apexigen, and Centrexion. With outstanding investment performance and exceptional research capabilities, Efung Capital has been honored with several prestigious awards, including Top 30 Healthcare Investment Institutions in China by Zero2IPO, Top 100 Venture Capital Institutions in China, Top 10 Best Exit Cases by ChinaVenture, Top 10 Best Biopharmaceutical Investment Institutions, Top 30 Best Healthcare Investment Institutions by Fund of Funds, and one of the most dynamic pharmaceutical innovation investment institutions in China. It has been consecutively ranked as one of “Shenzhen’s Top Ten Venture Capital Institutions” for multiple years and was featured in an exclusive interview by the world-renowned scientific journal *Nature*. Efung Capital aims to drive the industrialization of biotechnology achievements through capital and contribute to life sciences. After years of accumulation, Efung Capital has embraced the philosophy of being "entrepreneur-centered and value-creator-focused," building a professional investment team with rich experience and distinct characteristics. The firm adheres to a systematic operation model that integrates investment, financing, risk control, management, and services, striving to become a people-oriented, trustworthy, and enduringly excellent investment institution.